Latest Taysha Gene Therapies News & Updates

See the latest news and media coverage for Taysha. We track all announcements, press releases, and industry mentions in real time, all in one place.

Taysha Gene Therapies (Taysha)

Gene therapy company for CNS monogenic diseases

tayshagtx.com

Headquarters: Dallas, United States
Founded year: 2020
Company type: Public company
Number of employees: 125–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Taysha Gene Therapies (Taysha)

In short: Taysha completed dosing in the pivotal TSHA-102 trial for Rett syndrome, expanded manufacturing with Catalent, and raised capital ahead of data in 1H 2027.

Company announcements

August 11 Taysha

Taysha reports Q2 2026 results and TSHA-102 progress

Completed dosing in pivotal and ASPIRE trials, reported $230M offering, and expects topline data and FDA feedback in 1H 2027.

August 3 Taysha

Taysha expands Catalent partnership for TSHA-102 manufacturing

Catalent will serve as primary commercial manufacturer at its FDA-licensed facility in Maryland, supporting potential launch.

June 25 Taysha

Taysha announces multiple presentations on TSHA-102 at IRSF meeting

Presentations highlight REVEAL Part A data showing multi-domain functional impact and new insights for pivotal trial design.

June 24 Taysha

Taysha announces proposed $200M public offering of common stock

The offering includes common stock and pre-funded warrants, with underwriters' option for additional 15%.

Media coverage

Today CGTLive

Taysha Doses First Pediatric Patient With Rett Syndrome With Gene Therapy TSHA-102 | CGTlive®

The first pediatric patient was treated in the United States, but the company has now also received clearance to treat pediatric patients in the UK.

August 20 Simply Wall St

TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - Simply Wall St News

Taysha Gene Therapies recently reported second-quarter 2026 results showing a net loss of US$46.64 million and basic loss per share of US$0.13, while also completing...

August 13 Yahoo Finance

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response...

August 12 Investing.com

Why are Taysha Gene Therapies shares falling today? By Investing.com

Investing.com -- Shares of Taysha Gene Therapies fell 7.0% during the morning session after the clinical-stage biotech reported...

Never miss news about Taysha

Track Taysha and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Taysha competitors & trending companies

Browse news for competitors to Taysha and other trending companies.